MPM Oncology Impact Management »

Xeris Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Xeris Pharmaceuticals (XERS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Xeris Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Xeris Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xeris Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $11M 4.8M 2.25
2024-03-31 $9.2M 4.2M 2.21
2023-09-30 $7.4M 4.0M 1.86
2023-06-30 $10M 4.0M 2.62

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Xeris Pharmaceuticals

BlackRock
BlackRock
Vanguard Group
MPM Oncology Impact Management
CenterBook Partners
Geode Capital Management
State Street Corporation
Rosalind Advisors
AIGH Capital Management
Morgan Stanley
Renaissance Technologies
Nuveen Asset Management
Northern Trust
AQR Capital Management
Redmile Group

View all funds holding Xeris Pharmaceuticals